GRDN Stock Forecast & Price Target

Guardian Pharmacy Service is a pharmacy services company with a strong position in the fragmented long-term care pharmacy industry, offering high-touch clinical services and technology solutions to improve outcomes. The company's recent outperformance in vaccine volumes and its ability to optimize its Medicare Part D mix and improve reimbursement are driving its raised guidance and sustainable earnings growth. The company's clean balance sheet and robust M&A pipeline also present potential opportunity for expansion and earnings growth. As the long-term care market continues to grow, Guardian Pharmacy Service is well positioned to benefit from its proven operating model, technology capabilities, and financial flexibility. There are risks, including potential regulatory changes and supply chain disruptions, but overall, we believe Guardian Pharmacy Service is a strong investment opportunity with its growth potential and position in the industry.

Guardian Pharmacy Service is experiencing quicker integration due to the implementation of purchasing and reimbursement programs and onboarding national accounts, resulting in 90 bps of adj. EBITDA margin upside. With strong 4Q results and a raised 2026 guidance, the company is expected to have LDD normalized adjusted EBITDA growth and better margins. The robust FCF and financial flexibility present opportunities for ongoing development and M&A, leading to a 'Buy' recommendation and a $38 price target.